[go: up one dir, main page]

MA30053B1 - Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires . - Google Patents

Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires .

Info

Publication number
MA30053B1
MA30053B1 MA31035A MA31035A MA30053B1 MA 30053 B1 MA30053 B1 MA 30053B1 MA 31035 A MA31035 A MA 31035A MA 31035 A MA31035 A MA 31035A MA 30053 B1 MA30053 B1 MA 30053B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
ikk
thiophen
pyrimidin
Prior art date
Application number
MA31035A
Other languages
English (en)
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Chuan Shih
Q May Wang
Bo Zhang
Michael Enrico Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA30053B1 publication Critical patent/MA30053B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule (I) : utilisables pour le traitement du cancer et des maladies inflammatoires.
MA31035A 2005-11-18 2008-06-13 Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires . MA30053B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
MA30053B1 true MA30053B1 (fr) 2008-12-01

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31035A MA30053B1 (fr) 2005-11-18 2008-06-13 Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires .

Country Status (27)

Country Link
US (1) US7547691B2 (fr)
EP (1) EP1989200B1 (fr)
JP (1) JP2009516697A (fr)
KR (1) KR100990771B1 (fr)
CN (1) CN101309918B (fr)
AR (1) AR057911A1 (fr)
AT (1) ATE437873T1 (fr)
AU (1) AU2006337626B2 (fr)
BR (1) BRPI0618245A2 (fr)
CA (1) CA2629336A1 (fr)
CR (1) CR9947A (fr)
DE (1) DE602006008187D1 (fr)
DK (1) DK1989200T3 (fr)
EA (1) EA014426B1 (fr)
EC (1) ECSP088456A (fr)
ES (1) ES2329085T3 (fr)
IL (1) IL190489A0 (fr)
MA (1) MA30053B1 (fr)
NO (1) NO20082594L (fr)
PE (1) PE20070833A1 (fr)
PL (1) PL1989200T3 (fr)
PT (1) PT1989200E (fr)
SI (1) SI1989200T1 (fr)
TN (1) TNSN08227A1 (fr)
TW (1) TW200800201A (fr)
WO (1) WO2007092095A2 (fr)
ZA (1) ZA200803940B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5066175B2 (ja) 2006-03-31 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
ATE485291T1 (de) 2006-12-21 2010-11-15 Lilly Co Eli Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
EP2125793B1 (fr) * 2006-12-21 2010-09-01 Eli Lilly & Company Composés imidazolidinonyl aminopyrimidine pour le traitement du cancer
CL2008001323A1 (es) 2007-05-16 2009-05-29 Lilly Co Eli Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CN101679396B (zh) 2007-05-16 2012-06-06 伊莱利利公司 三唑基氨基嘧啶化合物
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
NZ590170A (en) 2008-06-30 2012-04-27 Janssen Pharmaceutica Nv Process for the preparation of substituted pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
RU2552999C2 (ru) 2010-04-27 2015-06-10 Хатчисон Медифарма Лимитед Соединения пиримидинилиндола
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
US10189825B2 (en) 2012-02-08 2019-01-29 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
US9796699B2 (en) 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
EP3490607A4 (fr) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. Composés et compositions, et utilisations associées
KR102811121B1 (ko) 2016-07-29 2025-05-22 스미토모 파마 아메리카, 인크. 화합물 및 조성물 및 이들의 용도
EP3573954A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
US11358959B2 (en) * 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
EP3573970A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
AU2020236225B2 (en) 2019-03-14 2025-12-18 Sumitomo Pharma America, Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CA2590939C (fr) * 2004-12-17 2011-10-18 Amgen Inc. Composes d'aminopyrimidine et procedes d'utilisation correspondants

Also Published As

Publication number Publication date
WO2007092095A3 (fr) 2007-11-08
DE602006008187D1 (de) 2009-09-10
EA200801362A1 (ru) 2009-02-27
TW200800201A (en) 2008-01-01
US7547691B2 (en) 2009-06-16
AR057911A1 (es) 2007-12-26
CR9947A (es) 2008-11-28
KR20080059451A (ko) 2008-06-27
IL190489A0 (en) 2008-11-03
SI1989200T1 (sl) 2009-12-31
EA014426B1 (ru) 2010-12-30
EP1989200A2 (fr) 2008-11-12
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (fr) 2007-08-16
ECSP088456A (es) 2008-06-30
CN101309918B (zh) 2010-12-29
DK1989200T3 (da) 2009-11-09
JP2009516697A (ja) 2009-04-23
AU2006337626A8 (en) 2008-06-19
ATE437873T1 (de) 2009-08-15
PL1989200T3 (pl) 2009-12-31
US20080306082A1 (en) 2008-12-11
WO2007092095A2 (fr) 2007-08-16
EP1989200B1 (fr) 2009-07-29
ES2329085T3 (es) 2009-11-20
ZA200803940B (en) 2009-09-30
NO20082594L (no) 2008-06-10
KR100990771B1 (ko) 2010-10-29
CN101309918A (zh) 2008-11-19
BRPI0618245A2 (pt) 2011-08-23
PE20070833A1 (es) 2007-08-27
AU2006337626B2 (en) 2012-03-22
PT1989200E (pt) 2009-10-12
TNSN08227A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
MA30053B1 (fr) Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires .
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
SV2009003233A (es) Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
YU90801A (sh) Supstituisani benzimidazoli
MXPA04004301A (es) Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
EP1615914A4 (fr) Antagonistes des recepteurs de cgrp
MA27771A1 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines utiles dans le traitement de l'hypertension
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
ATE537170T1 (de) Cgrp-rezeptorantagonisten
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
MA27549A1 (fr) N-sulfonyl-4-methylene-amino-3-hydroxy-2-pyridones
ATE407120T1 (de) 3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns
ATE467636T1 (de) Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten